Related Experiment Video

Updated: Nov 9, 2025

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

19.0K

Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells

Ariadna Recasens1, Sean J Humphrey2, Michael Ellis3

  • 1Charles Perkins Centre and School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2006, Australia. ariadna.recasens@sydney.edu.au.

Cell Death Discovery
|April 17, 2021
PubMed

Insights

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) plays a complex role in glioblastoma. Its inhibition

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) exhibits both tumor-suppressive and oncogenic functions.
  • The precise role of DYRK1A in glioblastoma remains incompletely understood.
  • Understanding DYRK1A's context-dependent signaling is crucial for cancer therapy.

Purpose of the Study:

  • To investigate the specific role of DYRK1A in glioblastoma.
  • To elucidate the molecular mechanisms by which DYRK1A influences glioblastoma cell behavior.
  • To determine how DYRK1A activity and retinoblastoma (RB) expression affect glioblastoma response to inhibition.

Main Methods:

  • Phosphoproteomic analysis to identify DYRK1A targets.
  • Mechanistic studies to understand protein degradation pathways.
  • Cellular assays to assess proliferation, cell cycle progression, and protein accumulation.
  • Experiments involving varying doses of DYRK1A inhibitors and assessment of RB status.

Main Results:

  • DYRK1A promotes cyclin B degradation by phosphorylating CDC23, a component of the anaphase-promoting complex.
  • DYRK1A inhibition causes cyclin B accumulation and CDK1 activation.
  • Glioblastoma cell response to DYRK1A inhibition is contingent on RB expression and inhibitor dosage.
  • Moderate inhibition with RB deficiency increases proliferation; RB proficiency leads to no change; complete inhibition causes cell cycle arrest irrespective of RB status.

Conclusions:

  • DYRK1A signaling in glioblastoma is complex and context-dependent.
  • The interplay between DYRK1A activity, RB status, and inhibitor concentration dictates cellular outcomes.
  • Targeting DYRK1A may offer therapeutic potential, but requires careful consideration of patient-specific factors and drug dosage.

More Related Videos

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk113:15

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1

Published on: February 25, 2016

12.1K
Assaying Protein Kinase Activity with Radiolabeled ATP08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

18.8K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.2K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
14.0K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

4.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K